Noradrenaline Kabi (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Noradrenaline Kabi, is a sympathomimetic presented as a sterile solution for injection for intravenous use. It acts as a potent vasopressor to raise blood pressure in patients with severe hypotension, septic shock, or cardiac arrest, primarily in intensive care environments.

GNH USA supplies Noradrenaline Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before distribution.

Noradrenaline Kabi is a vasopressor used in critical care to manage life‑threatening circulatory failure.

- Hypotension: restores arterial pressure by increasing systemic vascular resistance in patients with acute low blood pressure. - Septic shock: counteracts vasodilatory shock by raising mean arterial pressure to improve organ perfusion. - Cardiac arrest: provides immediate vasoconstrictive support during resuscitation to maintain coronary and cerebral perfusion.

Norepinephrine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache may occur. - Tremor: transient shaking of hands or limbs. - Nausea: occasional nausea or vomiting. - Palpitations: sensation of rapid or irregular heartbeat. - Anxiety: feeling of nervousness or restlessness. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Severe hypertension: excessive rise in blood pressure leading to vascular injury. - Cardiac arrhythmia: potentially life‑threatening irregular heart rhythms. - Peripheral ischemia: reduced blood flow to extremities causing pain or necrosis. - Lactate accumulation: metabolic acidosis risk. - Extravasation injury: tissue damage if solution leaks from vein.

Use of Noradrenaline Kabi requires careful monitoring and adherence to safety guidelines.

- Hemodynamic monitoring: continuously assess blood pressure and heart rate during infusion. - Dose titration: adjust infusion rate to achieve target mean arterial pressure. - Electrolyte balance: monitor serum potassium and calcium levels, correcting abnormalities. - Contraindications: avoid use in patients with uncorrected hypovolemia or pheochromocytoma. - Drug compatibility: administer through dedicated line; avoid mixing with solutions that may precipitate. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with several agents, influencing its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may blunt the chronotropic response, reducing heart rate increase. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis due to excess catecholamines. - Tricyclic antidepressants: additive vasoconstriction may cause severe hypertension.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may counteract norepinephrine’s pressor effect, requiring higher doses. - Calcium channel blockers: can enhance negative inotropic effects, necessitating cardiac monitoring. - Diuretics: volume depletion may potentiate hypotensive episodes if norepinephrine is tapered.